Allergan Sales, 4.375% 1feb2019, USD (FIGI RegS BBG005XWZR30, WKN A1ZD21)
International bonds
International bonds
Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market
Get accessBond parameters,
prospectuses
Analyze the data in the most efficient way
Current & historical quotes from 400+ stock exchanges & OTC market
Credit ratings, financial reports
Explore the most comprehensive database
1 000 000
bonds
80 234
stocks
167 970
ETF & Funds
70 000
indices
Track your portfolio in the most efficient way
full data on over 900 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.
Register|
Allergan Sales, LLC (f.n.a.Forest Laboratories, Inc. (Forest)) develops, manufactures and sells branded forms of ethical drug products, which requires a physician's prescription. The Company focuses on the development and introduction of new products, including products developed ...
Allergan Sales, LLC (f.n.a.Forest Laboratories, Inc. (Forest)) develops, manufactures and sells branded forms of ethical drug products, which requires a physician's prescription. The Company focuses on the development and introduction of new products, including products developed in collaboration with licensing partners. The Company’s products include Namenda, the Company's NMDA antagonist for the treatment of moderate to severe dementia of the Alzheimer's type; Bystolic is a beta-blocker for the treatment of hypertension; Linzess is a guanylate cyclase type-C receptor agonist for the once-daily treatment for men and women suffering from IBS-C or CIC; Tudorza is a long-acting antimuscarinic agent for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and Viibryd is an SSRI and a 5-HT1A receptor partial agonist for the treatment of adults with major depressive disorder (MDD).
|
|
|
|
|
|
|
|
|
Explore the most comprehensive database
1 000 000
bonds
80 234
stocks
167 970
ETF & Funds
70 000
indices
Track your portfolio in the most efficient way
full data on over 900 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.
Register